Results 11 to 20 of about 20,887 (223)

Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface [PDF]

Cancer Research, 2019
Abstract MYCN is a major driver for the childhood cancer, neuroblastoma, however, there are no inhibitors of this target. Enhanced MYCN protein stability is a key component of MYCN oncogenesis and is maintained by multiple feedforward expression loops involving MYCN transactivation target ...
Koach, J, Holien, JK, Massudi, H, Carter, DR, Ciampa, OC, Herath, M, Lim, T, Seneviratne, JA, Milazzo, G, Murray, JE, McCarroll, JA, Liu, B, Mayoh, C, Keenan, B, Stevenson, BW, Gorman, MA, Bell, JL, Doughty, L, Hüttelmaier, S, Oberthuer, A, Fischer, M, Gifford, AJ, Liu, T, Zhang, X, Zhu, S, Gustafson, WC, Haber, M, Norris, MD, Fletcher, JI, Perini, G, Parker, MW, Cheung, BB, Marshall, GM   +32 more
core   +10 more sources

Neuroblastoma and MYCN [PDF]

Cold Spring Harbor Perspectives in Medicine, 2013
Neuroblastoma, the most common extracranial solid tumor of childhood, is thought to originate from undifferentiated neural crest cells. Amplification of the MYC family member, MYCN, is found in ∼25% of cases and correlates with high-risk disease and poor prognosis.
Huang, Miller, Weiss, William A
openaire   +6 more sources

Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification [PDF]

Proceedings of the National Academy of Sciences, 2012
Neuroblastoma is a pediatric tumor of the sympathetic nervous system. MYCN (V-myc myelocytomatosis viral-related oncogene, neuroblastoma derived [avian]) is amplified in 20% of neuroblastomas, and these tumors carry a poor prognosis. However, tumors without MYCN
Valentijn, Linda J., Koster, Jan, Haneveld, Franciska, Aissa, Rachida Ait, van Sluis, Peter, Broekmans, Marloes E. C., Molenaar, Jan J., van Nes, Johan, Versteeg, Rogier   +8 more
openaire   +4 more sources

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma

Oncotarget, 2018
The MYC oncogenes and p53 have opposing yet interrelated roles in normal development and tumorigenesis. How MYCN expression alters the biology and clinical responsiveness of pediatric neuroblastoma remains poorly defined. Neuroblastoma is p53 wild type at diagnosis and repression of p53 signaling is required for tumorigenesis.
Agarwal, Saurabh, Milazzo, Giorgio, Rajapakshe, Kimal, Bernardi, Ronald, Chen, Zaowen, Barberi, Eveline, Koster, Jan, Perini, Giovanni, Coarfa, Cristian, Shohet, Jason M.   +9 more
openaire   +5 more sources

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors [PDF]

Oncotarget, 2016
MYC oncoproteins deliver a potent oncogenic stimulus in several human cancers, making them major targets for drug development, but efforts to deliver clinically practical therapeutics have not yet been realized. In childhood cancer, aberrant expression of MYC and MYCN genes delineates a group of aggressive tumours responsible for a major proportion of ...
Vaughan, L, Clarke, PA, Barker, K, Chanthery, Y, Gustafson, CW, Tucker, E, Renshaw, J, Raynaud, F, Li, X, Burke, R, Jamin, Y, Robinson, SP, Pearson, A, Maira, M, Weiss, WA, Workman, P, Chesler, L   +16 more
openaire   +6 more sources

RETRACTED: Targeting MYCN IRES in MYCN‐amplified neuroblastoma with miR‐375 inhibits tumor growth and sensitizes tumor cells to radiation

Molecular Oncology, 2015
The MYCN oncogene is amplified in 20% of neuroblastomas, leading to its overexpression at both the mRNA and protein levels. MYCN overexpression is strongly associated with advanced disease stage, rapid tumor progression and a worse prognosis.
Hailong Zhang, Tao Liu, Sha Yi, Lubing Gu, Muxiang Zhou   +4 more
doaj   +2 more sources

Targeting MYCN in Pediatric and Adult Cancers [PDF]

Frontiers in Oncology, 2021
The deregulation of the MYC family of oncogenes, including c-MYC, MYCN and MYCL occurs in many types of cancers, and is frequently associated with a poor prognosis.
Zhihui Liu, Samuel S. Chen, Saki Clarke, Veronica Veschi, Carol J. Thiele   +4 more
doaj   +2 more sources

Heterogeneity of the MYCN Oncogene in Neuroblastoma [PDF]

Clinical Cancer Research, 2009
Abstract Purpose: MYCN amplification is an important therapy-stratifying marker in neuroblastoma. Fluorescence in situ hybridization with signal detection on the single-cell level allows a critical judgement of MYCN intratumoral heterogeneity.
Theissen, J, Boensch, M, Spitz, R, Betts, D, Stegmaier, S, Christiansen, H, Niggli, F, Schilling, F, Schwab, M, Simon, T, Westermann, F, Berthold, F, Hero, B   +12 more
openaire   +3 more sources

MYCN Expression Is Not Prognostic of Adverse Outcome in Advanced-Stage Neuroblastoma With Nonamplified MYCN

Journal of Clinical Oncology, 2000
PURPOSE: The clinical significance of MYCN expression in children with neuroblastoma (NB) remains controversial. To determine the prognostic significance of MYCN expression in the absence of MYCN amplification, we analyzed MYCN mRNA and protein expression in tumors from 69 patients.
S L, Cohn, W B, London, D, Huang, H M, Katzenstein, H R, Salwen, T, Reinhart, J, Madafiglio, G M, Marshall, M D, Norris, M, Haber   +9 more
openaire   +3 more sources

MYCN and microRNAs in neuroblastoma [PDF]

, 2011
The papers and appendix in this thesis are not available in Munin due to publishers' restrictions: 1. Buechner J, Henriksen JR, Haug BH, Tomte E, Flaegstad T and Einvik C: 'Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells', Differentiation (2011) 81(1):25-
Büchner, Jochen
openaire   +2 more sources